SCHEMBL32673085

SCHEMBL32673085

FC(F)(F)Oc1ccccc1[C@@H](Cc1ccccn1)c1c[nH]cn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPRA P18433 1/20 0.36
GRIN2D O15399 1/20 0.35
GRIN3B O60391 1/20 0.35
GRIN1 Q05586 1/20 0.35
GRIN2A Q12879 1/20 0.35
GRIN2B Q13224 1/20 0.35
GRIN2C Q14957 1/20 0.35
GRIN3A Q8TCU5 1/20 0.35
PDE2A O00408 1/20 0.33
SLC6A4 P31645 3/20 0.32
CYP2D6 P10635 2/20 0.32
SLC6A2 P23975 2/20 0.32
KCNH2 Q12809 2/20 0.32
FDPS P14324 1/20 0.32
CETP P11597 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
LNPEP Q9UIQ6 1/20 0.31
ABCB1 P08183 1/20 0.31
HTR1A P08908 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32673107 1.00 PTPRA (0.36) PTPRAGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL32673183 0.86 SYK (0.39) PTPRAGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL32672776 0.86 SYK (0.39) PTPRAGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL32673094 0.81 GRIN2D (0.34) PTPRAGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL32672756 0.79 CETP (0.42) PTPRAGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL32673160 0.79 CETP (0.42) PTPRAGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL32672922 0.76 GRIN2D (0.35) PTPRAGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL32672980 0.76 GRIN2D (0.35) PTPRAGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL32672927 0.75 GRIN2D (0.37) PTPRAGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL32672879 0.75 GRIN2D (0.37) PTPRAGRIN2DGRIN3BGRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260042769-A1 TRIARYL AGONISTS OF ALPHA-2 ADRENERGIC RECEPTORS ALCEPTOR THERAPEUTICS INC (US) 2026-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260042769-A1 TRIARYL AGONISTS OF ALPHA-2 ADRENERGIC RECEPTORS ADRB2, ADRB1, ADRB3 PTPRA 3567/4885GRIN2D 672/4885GRIN3B 501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.